Zenas BioPharma, Inc.
ZBIO
$6.85
-$0.90-11.61%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -113.95% | -208.43% | -30.74% | -45.57% | -29.45% |
| Total Depreciation and Amortization | 10.00% | 38.46% | 20.69% | 17.86% | 20.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 223.96% | 152.17% | -83.20% | 105.01% | 165.89% |
| Change in Net Operating Assets | 17.17% | 191.54% | 286.14% | 187.21% | 508.28% |
| Cash from Operations | -150.35% | -197.53% | -48.04% | 26.71% | 10.08% |
| Capital Expenditure | -335.29% | -- | -- | -- | 77.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -21,870.59% | -- | -- | -- | 98.42% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 12,552.00% | -- | 1,027.27% | -23.64% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3,606.00% | 1,069.90% | 1,615,709.09% | -1,216.36% | -99.92% |
| Foreign Exchange rate Adjustments | 262.07% | -1,400.00% | -80.72% | 820.00% | -583.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -160.74% | 239.65% | 807.87% | 24.26% | -137.50% |
